Key statistics
52-week range
Open | 15.50 |
---|---|
High | 16.10 |
Low | 15.50 |
Bid | 15.80 |
Offer | 16.30 |
Previous close | 15.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 128.43m |
Free float | 113.32m |
P/E (TTM) | -- |
Market cap | 2.18bn USD |
EPS (TTM) | -1.56 USD |
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
- Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
- Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
- Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
- Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
- Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
- Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
- Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
More ▼